Lentris 4 mg and 10 mg are capsules manufactured by Mylan Pharmaceuticals Pvt Ltd, a Viatris Company. Each capsule contains lenvatinib, a receptor tyrosine kinase inhibitor used in cancer treatment.
Category | Antineoplastic |
Brand | Mylan |
Ingredient | lenvatinib |
Prescription Required | Yes |
Strength | 4/10mg |
Package | 10 Tablets |
Lentris 4 mg and 10 mg (lenvatinib) work by targeting and inhibiting multiple receptor tyrosine kinases that are crucial for the growth and spread of cancer cells. Lenvatinib blocks key receptors such as vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and others that are involved in tumor angiogenesis, the process by which tumors develop new blood vessels to supply themselves with oxygen and nutrients.
Lentris 4 mg and 10 mg tablets, containing the active ingredient lenvatinib, offer significant benefits in the treatment of various cancers. The primary advantage of Lentris lies in its ability to target multiple receptor tyrosine kinases involved in tumor angiogenesis—the process by which tumors form new blood vessels to support their growth. By inhibiting key receptors such as vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptors (FGFR), Lentris effectively reduces the blood supply to the tumor, limiting its ability to grow and spread.
The most common side effects of Lentris 4 and 10mg Tablet
• Fatigue
• Hypertension (high blood pressure)
• Diarrhea
• Decreased appetite
• Nausea
• Weight loss
• Stomatitis (inflammation of the mouth)
• Vomiting
• Abdominal pain
• Hand-foot syndrome (redness, swelling, or pain in the hands and feet)
• Headache
• Rash
• Constipation
• Dysphonia (hoarseness)
• Proteinuria (protein in urine)
Other side effects of Lentris 4 and 10mg Tablet
• Heart problems (e.g., congestive heart failure, arrhythmias)
• Severe liver problems (elevated liver enzymes, jaundice)
• Bleeding or blood clotting issues
• Hypothyroidism (underactive thyroid)
• Severe skin reactions (blistering, peeling, or severe rash)
• Increased risk of infection (due to immune system suppression)
• Severe gastrointestinal issues (such as gastrointestinal perforation or fistula)
• Severe fatigue or weakness
• Difficulty breathing or shortness of breath
• Muscle weakness or pain
• Electrolyte imbalances (e.g., low levels of calcium, magnesium, or potassium)
• Visual disturbances (such as blurred vision or vision loss)
Bosutris Lentris 4 and 10mg Tablet
Lentris 4 mg and 10 mg tablets (lenvatinib) should not be taken by individuals who have a known allergy or hypersensitivity to lenvatinib or any of its components. It is contraindicated for pregnant women, as the medication can cause severe birth defects or harm to the fetus. Women of childbearing age should use effective contraception during treatment and for some time after stopping the medication. Breastfeeding women should also avoid taking Lentris, as it may pass into breast milk and pose a risk to the infant.
Lentris 4 mg and 10 mg tablets (lenvatinib) should be taken exactly as prescribed by your healthcare provider. The usual dosage is one tablet taken once daily, at the same time each day, to help maintain consistent levels of the medication in your body. It is recommended to take the tablet orally, with or without food. The tablet should be swallowed whole with a glass of water and should not be crushed, chewed, or broken.
There are no reviews yet.